HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) earned approval from China’s National Medical Products Administration (NMPA) for Sulanda (surufatinib) for the treatment of non-pancreatic neuroendocrine tumors (NETs).
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) earned approval from China’s National Medical Products Administration (NMPA) for Sulanda (surufatinib) for the treatment of non-pancreatic neuroendocrine tumors (NETs), marking what CEO Christian Hogg called a “major milestone” as the first drug to be discovered and developed by Chi-Med without the support of a development partner.
HONG KONG – Hutchison China Meditech Ltd. (also known as Chi-Med) has received a $100 million equity investment from the Canada Pension Plan Investment Board, which will fund ongoing research, clinical development and commercialization capabilities.
HONG KONG – Hutchison China Meditech Ltd. (also known as Chi-Med) has received a $100 million equity investment from the Canada Pension Plan Investment Board, which will fund ongoing research and clinical development and support the further growth of its commercialization capabilities both in China and globally.
BEIJING – Hong Kong-headquartered Hutchison China Meditech Ltd.’s (Chi-Med) called an early stop to its phase III pivotal study of surufatinib in advanced pancreatic neuroendocrine tumors (NET) in China after it met the predefined primary endpoint of progression-free survival.
HONG KONG – Hong Kong-headquartered Hutchison China Meditech Ltd.’s (Chi-Med) NDA for surufatinib as a treatment for patients with advanced non-pancreatic neuroendocrine tumors (NET) has been accepted for review by China’s National Medical Products Administration (NMPA).